ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT
Delisted
ONCT was delisted on the 2nd of December, 2024.
61 hedge funds and large institutions have $8.79M invested in Oncternal Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
61
Holders Change
-14
Holders Change %
-18.67%
% of All Funds
1.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
12
Reduced
19
Closed
18
Calls
$65K
Puts
–
Net Calls
+$65K
Net Calls Change
+$88K
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
$2.55M |
| 2 |
Renaissance Technologies
New York
|
$874K |
| 3 |
Two Sigma Investments
New York
|
$318K |
| 4 |
Two Sigma Advisers
New York
|
$263K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
$171K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
$0 |
| 2 |
Millennium Management
New York
|
$522K |
| 3 |
Morgan Stanley
New York
|
$62K |
| 4 |
Goldman Sachs
New York
|
$12K |
| 5 |
UBS Group
Zurich,
Switzerland
|
$15K |
